TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02062203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548 (therapeutic dose)
Description: Single oral dose of AKB-6548 at a therapeutic dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548 (supratherapeutic dose)
Description: Single oral dose of AKB-6548 at a supratherapeutic dose level

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose of placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Single oral dose of 400 mg moxifloxacin
Study: NCT01332292

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Novel dry powder inhaler: One blister strip containing lactose and a second blister strip containing lactose and magnesium stearate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Novel dry powder inhaler: One blister strip containing lactose and a second blister strip containing lactose and magnesium stearate.
Study: NCT02039674

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV on Day 1 of each 3-week cycle
Study: NCT01704703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Panitumumab 6,0 mg/kg day 1 i.v. 60 min
Study: NCT02039674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV on Day 1 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV on Day 1 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV on Day 1 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV on Day 1 of each 3-week cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV on Day 1 of each 3-week cycle for a maximum of 4 administrations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV on Day 1 of each 3-week cycle for a maximum of 4 administrations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV on Day 1 of each 3-week cycle for a maximum of 4 administrations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV on Day 1 of each 3-week cycle for a maximum of 4 administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Orally tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Oral tablet once daily
Study: NCT01278485

Intervention type: DRUG
Intervention: Sulphonylurea
Description: SU administered according to usual practice.
Study: NCT01704703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Irinotecan 180 mg/m2 day 1 i.v. 30-90 min Folinic acid 400 mg/ m2 day 1 i.v. 120 min 5-FU 400 mg/ m2 day 1 Bolus 5-FU 2.400 mg/ m2 day 1 i.v. 46 hours
Study: NCT01278485

Intervention type: DRUG
Intervention: Metformn
Description: Metformin administered according to usual practice.
Study: NCT02561637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case management

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group
Study: NCT04097093

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01545050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-945429
Description: Injection, Intravenous (IV), 0 mg, Day One Only, One Day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-945429
Description: Injection, Intravenous (IV), 0 mg, Day One Only, One Day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-945429
Description: Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, 8 weeks
Study: NCT00469560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Study: NCT02692781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-6031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-6031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-6031
Study: NCT01545050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-945429
Description: Injection, Subcutaneous (SC), 0 mg, Week 4 Only, One Day
Study: NCT02692781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-6031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-6031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo control
Study: NCT01015066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine/naloxone
Description: Sublingual tablets, 2/0.5mg (ratio buprenorphine:naloxone = 4:1), three times a day for six months (doses may be adjusted based on an individual's response)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Oral tables, 50 mg/d, once a day for six months
Study: NCT04321291

Intervention type: OTHER
Group type: OTHER
Intervention: Generic information leaflet
Description: The information about the biosimiliars is realized only by the transmission of the information leaflet in addition to the information given by the investigator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual information by nurse on biosimilars
Description: Delivery of the same information leaflet, completed if asked by the patient, by individual meeting with specialist nurse, including generic and standardized informations on specificities, advantages and current scientific knowledge about biosimilars in inflammatory rheumatic diseases. This is in addition to the information given by the investigator
Study: NCT02692781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo control
Study: NCT01069146

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia induction
Description: Mild Therapeutic hypothermia was induced immediately after patient inclusion. Patients were cooled between 32 and 34°c (33 ± 1°C; 90 and 93°F) for 36 hours, using the automatic mode of an external water cooling blanket (Meditherm II®, Gaymar, Orchard Park, NY, USA). The machine constantly compares actual patient temperature (measured by a rectal probe) with the set point, and automatically adjusts the blanket water temperature so that the desired patient temperature is achieved. The target temperature was to be reached within eight hour following inclusion. Rewarming was only passive (blanket switched off), and paralytic agents were to be stopped when the body temperature reached back 36°C (97°F).
Study: NCT00166088

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: The Mediterranean diet group will receive all meals as a prototypical Mediterranean diet for 4 consecutive weeks prepared by the GCRC metabolic kitchen with dietary instruction. During the second month of the study they will be asked to follow a Mediterranean diet using their own home-cooked meals

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Dietary Supplement
Description: The subjects randomized to the typical diet + targeted Mediterranean dietary supplement group will not receive dietary counseling. They will be given a one-month supply of specific supplements by the GCRC nutritionists and advised to consume these daily, in addition to their usual diet.
Study: NCT02084147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo PET

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo CT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo MRI
Study: NCT04142554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib tablets (1.0, 2.5 or 5 mg) are administered orally daily for up to 14 days
Study: NCT04212260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oropharyngeal exercises
Description: Oro-pharyngeal exercises that improve oro-pharyngeal and tongue strength. Instructions will be delivered via a tablet-based app.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: Simple mouth movements that have no impact of oro-pharyngeal strength. Instructions will be delivered via a tablet-based app.
Study: NCT01682902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
Study: NCT04665583

Intervention type: OTHER
Intervention: Prehabilitation
Description: Prehabilitation will consist of careful pre-intervention assessment and personalized optimization, guided by Investigator judgment, with a specific focus on right ventricular function. This will be done by using a detailed echo acquisition protocol (Appendix 1). Assessments will be collected according to the schedule of events below (Table 1.). Therapy will include intravenous milrinone therapy and aggressive diuresis with evaluation for clinical and functional signs of improvement, according to standard of care.
Study: NCT01682902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
Study: NCT02910076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200 MG Plaquenil three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200 MG Plaquenil three times a day
Study: NCT04689295

Intervention type: OTHER
Group type: OTHER
Intervention: exercise programme 1
Description: Schroth three dimensional scoliosis therapy method
Study: NCT00377832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 975 mg
Description: Acetaminophen 975 mg by mouth once only
Study: NCT01959373

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electroencephalograms (EEG)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electroencephalograms (EEG)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electro-myography (EMG)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electro-myography (EMG)
Study: NCT02272257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Direct Access Physical Therapy
Description: Physical Therapy management including Manual therapy, Exercise, and education including cognitive behavioral therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician management
Description: Physician management including advice, medication, and referral to physical therapy or other provider.
Study: NCT01545050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-945429
Description: Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, Up to 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Intravenous (IV), 600 mg, Day One Only, One Day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous (SC), 200 mg, Week 8 only, One Day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous (SC), 200 mg, Week 8 only, One Day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Intravenous (IV), 300 mg, Day One Only, One Day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous (SC), 100 mg, Week 8 Only, One Day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous (SC), 100 mg, Week 8 Only, One Day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous (SC), 400 mg, Day One and Week 4, 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Intravenous (IV), 150 mg, Day One Only, One Day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous (SC), 100 mg, Every 4 weeks, Up to 48 weeks
Study: NCT02543762

Intervention type: PROCEDURE
Intervention: Chromoendoscopy
Description: Chromoendoscopy involves the topical application of stains to improve tissue localization and characterization of lessions during endoscopy . Chromoendoscopy has been used in patients undergoing colonoscopy, including those undergoing surveillance for chronic ulcerative colitis. Using pit pattern classifications, chromoendoscopy has a high sensitivity and specificity for differentiating neoplastic from non-neoplastic lesions
Study: NCT03713632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: Secukinumab 300mg every 2 or every 4 weeks
Study: NCT01545050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 48 weeks
Study: NCT03967015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal Administered Malnutrition Monitoring System (MAMMS)
Description: Participants randomized to the MAMMS arm will be provided with two insertion MUAC tapes that are UNICEF color coded and numbered to 1 mm gradations to take home with them. Participants will receive a weekly SMS asking them to measure and send their child's MUAC via SMS. SMS messages will provide actionable reminders to measure and send the child's MUAC. Both the SMS sent to the participant and SMS responses sent by the participant to the MAMMS system will be free of charge. Study staff will screen all SMS measurements returned to the MUAC system for identification of malnutrition.
Study: NCT04689295

Intervention type: OTHER
Group type: OTHER
Intervention: exercise programme 2
Description: Traditional scoliosis exercises
Study: NCT03913884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Concentrated growth factor
Description: CGF fibrin matrix was placed in one socket which was randomly selected (test side). The flap was sutured with 4/0 atraumatic silk suture (½ cutting edge, 75 cm, Doğsan, İstanbul, Turkey) for each surgical site.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Concentrated growth factor Group
Description: To control group, extraction of the tooth on the opposite site was performed and the socket left to heal naturally. The flap was sutured with 4/0 atraumatic silk suture (½ cutting edge, 75 cm, Doğsan, İstanbul, Turkey) for each surgical site.
Study: NCT03713632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: Secukinumab 300mg every 2 or every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 300mg every 2 or every 4 weeks
Study: NCT02629666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ERS and/or Self-management Strategies
Study: NCT01545050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 96 weeks, depending on when subject enters this period
Study: NCT02540291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7046
Description: E7046 will be administered as a single agent orally once daily (QD) continuously in 21-day cycles. In the dose escalation part, increasing doses of E7046 ranging from 125 mg to 750 mg will be administered to cohorts of 6 participants. In the cohort expansion part, participants will be treated at the RP2D.
Study: NCT03713632

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 300mg every 2 or every 4 weeks
Study: NCT01420419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lanolin
Description: Pea-sized amount of lanolin applied to each nipple after every breastfeeding session (approximately 8-12 times daily) until complete resolution of nipple pain and damage for a maximum of 7 days.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard (usual) in-hospital and community postpartum care
Description: Women randomized to standard care will not receive lanolin or information regarding how to use lanolin. In-hospital standard care may include any of the following pain management measures at the recommendation / discretion of the participant's health care provider, or based on the patient's personal preference: analgesics (such as ibuprofen or acetaminophen); application of cold or warm compresses; application of ice packs; use of breast shields; air drying the nipples; or applying expressed breast milk.
Study: NCT04293367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Description: HIIT involves exercising in blocks of time (typically 4-5 minutes) where a small percentage of the time (typically 1 minute) is spent above the anaerobic (lactate) threshold (the work interval) followed by the remainder of the time at a sub-anaerobic threshold (active recovery).
Study: NCT00126984

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conjugated meningococcal ACWY-TT (vaccine)
Description: One intramuscular dose during the primary vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conjugated meningococcal ACWY-TT (vaccine)
Description: One intramuscular dose during the primary vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conjugated meningococcal ACWY-TT (vaccine)
Description: One intramuscular dose during the primary vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conjugated meningococcal ACWY-TT (vaccine)
Description: One intramuscular dose during the primary vaccination
Study: NCT02765425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMES
Description: Subjects will be trained while seated on the AMES device. As the footplate of the device rotates the ankle ±15 deg in dorsiflexion and plantarflexion, the participant will assist that motion. Vibration (2-3 mm at 60 pulses/s) will be applied to the tibialis anterior tendon during plantarflexion and to the Achilles tendon during dorsiflexion. To assist participants in the assisted movement task, the AMES biofeedback screen will provide real-time visual feedback of the volitional ankle torque that the participants actively apply to the AMES device. Each training session will include 15 min of training of each ankle; training sessions will be conducted 3 times/week over a 12-week period, for a total of 9 hours of training on each ankle.
Study: NCT04303780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 510
Description: 21 day cycles
Study: NCT00126984

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa/Hib containing vaccine
Description: One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa/Hib containing vaccine
Description: One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa/Hib containing vaccine
Description: One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa/Hib containing vaccine
Description: One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTPa/Hib containing vaccine
Description: One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec
Description: One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mencevax ACWY
Description: One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (group E) and subcutaneous administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (group C, group E)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mencevax ACWY
Description: One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (group E) and subcutaneous administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (group C, group E)
Study: NCT03551665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protective step training
Description: Participants will undergo 2 weeks of training, in which they will be exposed to repeated slips on a treadmill. This approach is aimed at improving protective steps.
Study: NCT03256435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RAMP PrEP initiation, adherence, and retention intervention
Description: The intervention arm will receive facilitated strengths-based case management (SBCM)-delivered by trained interventionists-to help navigate the PrEP medical care system and support the participant and health care staff in meeting the challenges faced with obtaining PrEP medication (e.g., overcoming insurance barriers or barriers with co-pays). This also includes facilitated integration into the PrEP clinic and obtaining monthly PrEP prescription refills.
Study: NCT03661086

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: O2matic
Description: O2matic controls oxygen with the aim of maintaining SpO2 within a predefined target interval, e.g. 88-92 % with the lowest possible supplementation of oxygen by nasal cannula
Study: NCT03400813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: R-TEP EMDR
Description: Recent Traumatic Episode Protocol Eye-Movement Desensitization and Reprocessing is a early and short adaption protocol of EMDR developed by Shapiro E. EMDR is a psychotherapeutic approach that can rapidly process disturbing experiences adaptively together with the aid of eye movements or other forms of bi-lateral stimulation.